Brief: Glenmark Pharmaceuticals Approved Sale Of 75% Of Glenmark Life Sciences To Nirma

Alivus Life Sciences

21/09/2023 14:19

Sept 21 (Reuters) - Glenmark Pharmaceuticals Ltd
 GLEN.NS :
    * APPROVED SALE OF 75.00% OF GLENMARK LIFE SCIENCES TO NIRMA
    * DEAL FOR 615 RUPEES PER SHARE, AGGREGATING TO 56.52
BILLION
RUPEES
    * GLENMARK PHARMA WILL CONTINUE TO OWN 7.84% IN GLENMARK
LIFE
SCIENCES
    * NIRMA WILL MAKE A MANDATORY OPEN OFFER TO ALL PUBLIC
SHAREHOLDERS OF GLS

Source text for Eikon:  ID:nBSE5SH31y 
Further company coverage:  GLEN.NS 

 ((Reuters.Briefs@thomsonreuters.com;))